This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Tesaro Inc. (oncology therapies) publicly sold 5.35mm common shares (including the overallotment) at $81 for net proceeds of $409mm. Some of the money will fund commercialization of Varubi (rolapitant) and rolapitant IV, both indicated for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy. Proceeds will also support ongoing trials for niraparib (in Phase III for ovarian and breast cancers) and additional immuno-oncology projects in the company's pipeline.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?